Eli Lilly will invest an additional $50 million in a global partnership to fight multidrug-resistant tuberculosis (MDR-TB). This new commitment brings the total Lilly investment to $120 million.
"Eli Lilly and Company understands its role in the global battle against MDR-TB and recognizes its responsibility to those afflicted by this deadly disease," remarks Sidney Taurel, chairman and CEO. "These additional funds will extend our commitment to transferring the technologies and improving the support systems needed to stop the spread of MDR-TB."
The funding supports a multipronged strategy to increase the supply and availability of effective drugs for treating the disease, training for front-line healthcare personnel, and efforts to focus global resources on prevention, diagnosis, and treatment of MDR-TB.
The Lilly MDR-TB Partnership is an international alliance of 14 public and private organizations, including businesses, humanitarian organizations, academic institutions, professional healthcare associations, and government centers.
A centerpiece of Lilly's MDR-TB Partnership is the transfer of technologies and expertise needed to manufacture two Lilly antibiotics used to treat MDR-TB, capreomycin (Capastat®) and cycloserine (Seromycin®), to facilities in the highest-burdened countries. In addition to supplying the necessary manufacturing know-how to produce the drugs, Lilly says that it provides financial assistance for the purchase of equipment and conversion of manufacturing facilities.